112
Lineage Cell Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
60.0
FY23:
38.4
FY24:
51.0
FY25:
59.2
(positive)
Change from FY21 to FY25
millions USD
FY21:
63.0
FY22:
63.7
FY23:
62.6
FY24:
62.2
FY25:
53.4
Total assets
Change from FY21 to FY25
millions USD
FY21:
175
FY22:
124
FY23:
101
FY24:
113
FY25:
113
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
47.1
FY22:
19.0
FY23:
18.0
FY24:
14.0
FY25:
11.4
(negative)
Change from FY21 to FY25
millions USD
FY21:
36.5
FY22:
32.7
FY23:
21.0
FY24:
22.2
FY25:
57.9
(positive)
Change from FY21 to FY25
millions USD
FY21:
92.2
FY22:
73.3
FY23:
63.4
FY24:
78.4
FY25:
44.5
All amounts in millions USD